Benefits outweigh the risk: Johnson & Johnson's European vaccine rollout resumes

Benefits outweigh the risk: Johnson & Johnson’s European rollout resumes

Johnson & Johnson sign

Flickr / Open Grid Scheduler

Johnson & Johnson is resuming its rollout in Europe after the EU drugs regulator said the vaccine may be linked to extremely rare blood clots but that its benefits far outweigh its risks.

The European regulator said the vaccine should carry a warning. It will be up to individual EU countries to decide whether and how to distribute the J&J vaccine. On Friday, a panel for the Centers for Disease Control and Prevention will meet to make recommendations on its use in the U.S., which has been temporarily halted.

This article is republished from Democracy Now under a Creative Commons license. Read the original article.

You May Also Like:

Back To Front Page